Mesothelin as a potential therapeutic target in human cholangiocarcinoma

Journal of Cancer

Volumn 1, Issue 1, 2010, Pages 141-149

  Yu, Liping ^a,b   Feng, Mingqian ^a   Kim, Heungnam ^a   Phung, Yen ^a   Kleiner, David E ^a   Gores, Gregory J ^c   Qian, Min ^b   Wang, Xin Wei ^a   Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

Author keywords

Bile duct carcinoma; Cholangiocarcinoma; Hepatocellular carcinoma; Immunotoxin; Mesothelin; SS1P

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOTOXIN; MESOTHELIN; SS 1 P; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL MEMBRANE; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 80052864402     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.1.141     Document Type: Article

References (35)

1. Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2009; 6:423-32.
2. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010; 101:579-85.
3. Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol. 2009; 7:S68-78.
4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33:1353-7.
5. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; 24:115-25.
6. Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist. 2006; 11:913-22.
7. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004; 24:189-99.
8. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol. 2007; 19:615-7.
9. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992; 50:373-81.
10. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7:3862-8.
11. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, et al. Mesothelin expression in human lung cancer. Clin Cancer Res. 2007; 13:1571-5.
12. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996; 93:136-40.
13. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004; 279:9190-8.
14. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5:50-65.
15. Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2009; 284:3739-49.
16. Lopez JB, Balasegaram M, Timor J, Thambyrajah V. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma. Malays J Pathol. 1997; 19:53-8.
17. Su WC, Chan KK, Lin XZ, Lin PW, Chow NH, Shin JS, et al. A clinical study of 130 patients with biliary tract cancers and periampullary tumors. Oncology. 1996; 53:488-93.
18. Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev. 2006; 15:1751.
19. Scholler N, Fu N, Yang Y, Ye Z, Goodmn GE, Hellström KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA. 1999; 96:11531-6.
20. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Kierk N, et al. Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer. 2005; 49(Suppl 1):S109-11.
21. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006; 12:447-53.
22. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006; 15:1014-20.
23. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005; 11:3814-20.
24. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6:559-65.
25. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008; 44:46-53.
26. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007; 7:20.
27. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res. 2005; 11:5840-6.
28. McShane LM, Altma DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. J Natl Cancer Inst. 2005; 97:1180-4.
29. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005; 124:838-45.
30. Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol. 1992; 28:136-42.
31. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362:1273-81.
32. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003; 27:1418-28.
33. Sirica AE, Zhang Z, Lai GH, Asano T, Shen XN, Ward DJ, et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2008; 47:1178-90.
34. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res. 2006; 12:4695-701.
35. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res. 2010; 70:1082-9.